Zydus Lifesciences Ltd has received final approval from the United States Food and Drug Administration (USFDA) to market Pemetrexed for Injection, in the strengths of 100 mg/vial,500 mg/vial, and 1000 mg/vial Single-Dose Vials (USRLD: Alimta). Pemetrexed is used to treat certain types of cancers such as lung cancer, mesothelioma.
It is a chemotherapy drug that works by slowing or stopping the growth of cancer cells. The drug will be manufactured at Zydus Hospira. Pemetrexed for Injection has a market size of USD 1,236 mn (as per IQVIA MAT March’22).
The group now has 314 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.
Subscribe to PharmaTutor News Alerts by Email
.png)
